4.7 Article

LncRNA CRNDE Promotes ATG4B-Mediated Autophagy and Alleviates the Sensitivity of Sorafenib in Hepatocellular Carcinoma Cells

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.687524

Keywords

hepatocellular carcinoma; CRNDE; ATG4B; autophagy; sorafenib

Funding

  1. National Natural Science Foundation of China [81872024, 31671464, 82073300]
  2. Natural Science Foundation of Chongqing [cstc2017jcyjBX0079, cstc2018jcyjA2018]
  3. Open Fund Research Projects of the State Key Laboratory of Cancer Biology of Air Force Medical University [CBSKL2019ZDKF07]
  4. Basic and Clinical Integration Research Project of Army Medical University [2019JCLC04]

Ask authors/readers for more resources

Research revealed that long non-coding RNA CRNDE induces autophagy in HCC cells by upregulating ATG4B, leading to increased resistance to sorafenib. Furthermore, silencing CRNDE can enhance the sensitivity of HCC cells to sorafenib.
Autophagy is closely related to the growth and drug resistance of cancer cells, and autophagy related 4B (ATG4B) performs a crucial role in the process of autophagy. The long non-coding RNA (lncRNA) colorectal neoplasia differentially expressed (CRNDE) promotes the progression of hepatocellular carcinoma (HCC), but it is unclear whether the tumor-promoting effect of CRNDE is associated with the regulation of ATG4B and autophagy. Herein, we for the first time demonstrated that CRNDE triggered autophagy via upregulating ATG4B in HCC cells. Mechanistically, CRNDE enhanced the stability of ATG4B mRNA by sequestrating miR-543, leading to the elevation of ATG4B and autophagy in HCC cells. Moreover, sorafenib induced CRNDE and ATG4B as well as autophagy in HCC cells. Knockdown of CRNDE sensitized HCC cells to sorafenib in vitro and in vivo. Collectively, these results reveal that CRNDE drives ATG4B-mediated autophagy, which attenuates the sensitivity of sorafenib in HCC cells, suggesting that the pathway CRNDE/ATG4B/autophagy may be a novel target to develop sensitizing measures of sorafenib in HCC treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available